New York, NY -- (SBWIRE) -- 12/10/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG), SUPERVALU INC (NYSE:SVU), Intel Corporation (NASDAQ:INTC), Cellceutix Corp (OTCMKTS:CTIX)
Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) showed a volume of 3.20 million shares by the end of last trade whereas the average volume of the stock remained 159,072.00 shares. The stock opened the session at $3.42 but then moved to $3.09. At that price, the stock showed a positive performance of 2.32%. Rosetta Genomics Ltd., is seeking to develop and commercialize diagnostic tests based on discovered group of genes known as microRNAs. The Company has established a clinical laboratory improvement amendment (CLIA)-certified laboratory in Philadelphia, which enables it to develop, validate and commercialize its own diagnostic tests applying its microRNA technology. In July 2011, the Company launched its fifth product - miRview lung. As of December 31, 2011, the Company launched five tests based on its five microRNA technologies: miRview mets; miRview mets2; miRview squamous; miRview meso, and miRview lung.
Will ROSG Continue To Move Higher? Find Out Here
SUPERVALU INC (NYSE:SVU) opened the session at $6.40 and closed the session at $6.31. The stock showed a negative performance of -0.79% in previous trading session. SUPERVALU INC. (SUPERVALU) is a United States grocery channel. It operates in three segments: Retail food, Save-A-Lot and Independent business. The Company leverages its distribution operations by providing wholesale distribution and logistics and service solutions to its independent retail customers through its Independent business segment. The Retail Food and Save-A-Lot reportable segments derive revenues from the sale of groceries at retail locations operated by the Company.
Has SVU Found The Bottom And Ready To Gain Momentum? Find Out Here
Intel Corporation (NASDAQ:INTC) opened the session at $24.84 and closed the session at $24.93. The stock showed a positive performance of 0.44% in previous trading session. The beta of the stock remained 0.93. Intel Corporation designs and manufactures integrated digital technology platforms. A platform consists of a microprocessor and chipset. The Company’s platforms are used in a range of applications, such as personal computers (PCs) (including Ultrabook systems), data centers, tablets, smartphones, automobiles, automated factory systems and medical devices. In February 2013, it acquired ProFUSION-Comercio e Prestacao de Servicos em Tecnologia da Informacao Ltda.
Why Should Investors Buy INTC After The Recent Gain? Just Go Here and Find Out
Cellceutix Corp (OTCMKTS:CTIX) the stock advanced 2.41% and finished the session at $1.62. Traded with volume of 253,454.00 shares in the prior session and the average volume of the stock remained 163,641.00 shares. The beta of the stock remained 0.20. Cellceutix Corporation is an early-stage developmental biopharmaceutical company. The Company has acquired exclusive rights to eight different pharmaceutical compound candidates that are designed for treatment of diseases which exist, or may exist in the future. The Company focuses on Phase 1 trial at Dana Farber Cancer Center and Beth Israel Deaconess Hospital for its anti-cancer compound,
Will CTIX Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)